These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24452008)

  • 1. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
    Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
    Manjula S; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
    Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
    J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
    Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
    Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
    May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
    Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.
    Wang H; Cui W; Guo C; Chen BZ; Ji M
    Biochem Cell Biol; 2016 Apr; 94(2):147-58. PubMed ID: 26836778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
    Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
    Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.
    Akher FB; Farrokhzadeh A; Ramharack P; Shunmugam L; Van Heerden FR; Soliman MES
    Med Hypotheses; 2019 Nov; 132():109359. PubMed ID: 31466018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
    Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.
    Beaulieu PL
    IDrugs; 2010 Dec; 13(12):938-48. PubMed ID: 21154154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
    Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
    Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
    Elhefnawi M; ElGamacy M; Fares M
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance.
    Lam AM; Edwards TE; Mosley RT; Murakami E; Bansal S; Lugo C; Bao H; Otto MJ; Sofia MJ; Furman PA
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6861-9. PubMed ID: 25182647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.